-
1.发明申请Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors 审中-公开酰胺取代的吲唑和苯并三唑衍生物作为聚（ADP-核糖）聚合酶（PARP）抑制剂公开(公告)号：US20090275619A1
公开(公告)日：2009-11-05
申请号：US12225857
申请日：2007-04-02
申请人： Julia Boueres , Danila Branca , Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Federica Orvieto , Rita Scarpelli , Carsten Schultz-Fademrecht
发明人： Julia Boueres , Danila Branca , Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Federica Orvieto , Rita Scarpelli , Carsten Schultz-Fademrecht
IPC分类号： A61K31/416 , C07D231/56 , C07D249/16 , A61K31/415 , A61P35/00
CPC分类号： C07D231/56 , C07D249/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D409/12 , C07D413/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/10
摘要： The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
摘要翻译： 本发明涉及作为聚（ADP-核糖）聚合酶（PARP）的抑制剂的式（I）化合物及其药学上可接受的盐或互变异构体，因此可用于治疗癌症，炎性疾病，再灌注损伤，缺血状况， 中风，肾衰竭，心血管疾病，心血管疾病以外的血管疾病，糖尿病，神经变性疾病，逆转录病毒感染，视网膜损伤或皮肤衰老以及紫外线诱发的皮肤损伤，以及用于癌症治疗的化学或放射增敏剂。
-
2.发明申请AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS 审中-公开作为聚（ADP-赖酮）聚合酶（PARP）抑制剂的酰胺取代的吲哚并苯并噻唑衍生物公开(公告)号：US20110201657A1
公开(公告)日：2011-08-18
申请号：US13091427
申请日：2011-04-21
申请人： Julia Boueres , Danila Branca , Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Federica Orvieto , Rita Scarpelli , Carsten Schultz-Fademrecht
发明人： Julia Boueres , Danila Branca , Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Federica Orvieto , Rita Scarpelli , Carsten Schultz-Fademrecht
IPC分类号： A61K31/4192 , C07D249/20 , A61P9/10 , A61P35/00 , A61P29/00 , A61P3/10 , A61P25/28 , A61P17/00 , A61P27/02 , A61P31/14
CPC分类号： C07D231/56 , C07D249/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D409/12 , C07D413/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D491/10
摘要： The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
摘要翻译： 本发明涉及作为聚（ADP-核糖）聚合酶（PARP）的抑制剂的式（I）化合物及其药学上可接受的盐或互变异构体，因此可用于治疗癌症，炎性疾病，再灌注损伤，缺血状况， 中风，肾衰竭，心血管疾病，心血管疾病以外的血管疾病，糖尿病，神经变性疾病，逆转录病毒感染，视网膜损伤或皮肤衰老以及紫外线诱发的皮肤损伤，以及用于癌症治疗的化学或放射增敏剂。
-
3.发明申请Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors 有权噻吩和噻唑取代三氟乙酮衍生物作为组蛋白脱乙酰酶（HDAC）抑制剂公开(公告)号：US20090076101A1
公开(公告)日：2009-03-19
申请号：US12223943
申请日：2007-02-14
申请人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
发明人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
IPC分类号： A61K31/426 , C07D333/28 , A61K31/381 , A61P11/00 , A61P3/00 , A61P25/00 , A61P29/00 , C07D277/20
CPC分类号： C07D333/22 , C07D409/04 , C07D413/04 , C07D417/04
摘要： The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐和互变异构体。 本发明化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 它们也可用于治疗神经变性疾病，精神发育迟滞，10精神分裂症，炎性疾病，再狭窄，免疫疾病，糖尿病，心血管疾病和哮喘。
-
4.发明授权Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors 有权噻吩和噻唑取代的三氟乙酮衍生物作为组蛋白脱乙酰酶（HDAC）抑制剂公开(公告)号：US07799825B2
公开(公告)日：2010-09-21
申请号：US12223943
申请日：2007-02-14
申请人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
发明人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
IPC分类号： A61K31/381 , C07D333/04
CPC分类号： C07D333/22 , C07D409/04 , C07D413/04 , C07D417/04
摘要： The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐和互变异构体。 本发明化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 它们也可用于治疗神经变性疾病，精神发育迟滞，10精神分裂症，炎性疾病，再狭窄，免疫疾病，糖尿病，心血管疾病和哮喘。
-
5.发明授权Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors 有权噻吩和噻唑取代的三氟乙酮衍生物作为组蛋白脱乙酰酶（HDAC）抑制剂公开(公告)号：US07977374B2
公开(公告)日：2011-07-12
申请号：US11991576
申请日：2006-09-05
申请人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli
发明人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli
IPC分类号： A61K31/381 , A61K31/496 , C07D333/02 , C07D333/10
CPC分类号： C07D409/08 , C07D277/56 , C07D333/34 , C07D333/38 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/10 , C07D495/04 , C12Q1/34
摘要： The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.
摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐或立体异构体。 本发明的化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 此外，本发明的化合物可用于治疗神经变性疾病，精神分裂症和中风等疾病。
-
6.发明申请Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors 有权噻吩和噻唑取代的三氟乙酮衍生物作为组蛋白脱乙酰酶（Hdac）抑制剂公开(公告)号：US20090156591A1
公开(公告)日：2009-06-18
申请号：US11991576
申请日：2006-09-05
申请人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli
发明人： Federica Ferrigno , Philip Jones , Ester Muraglia , Jesus Maria Ontoria Ontoria , Rita Scarpelli
IPC分类号： A61K31/47 , C07D409/02 , C07D417/02 , C07D265/30 , A61K31/496 , A61K31/5375 , A61P25/18 , A61P25/28
CPC分类号： C07D409/08 , C07D277/56 , C07D333/34 , C07D333/38 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/10 , C07D495/04 , C12Q1/34
摘要： The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.
摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐或立体异构体。 本发明的化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 此外，本发明的化合物可用于治疗神经变性疾病，精神分裂症和中风等疾病。
-
7.发明授权Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors 有权杂环取代的酮衍生物作为组蛋白脱乙酰酶（HDAC）抑制剂公开(公告)号：US08026265B2
公开(公告)日：2011-09-27
申请号：US12086812
申请日：2006-12-21
申请人： Philip Jones , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Raffaele Ingenito , Carsten Schultz-Fademrecht
发明人： Philip Jones , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Raffaele Ingenito , Carsten Schultz-Fademrecht
IPC分类号： A61K31/415 , C07D233/00
CPC分类号： C07D233/64 , C07D401/12
摘要： The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
摘要翻译： 本发明涉及式（I）的化合物及其药学上可接受的盐和互变异构体。 本发明化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 它们也可用于治疗神经变性疾病，精神发育迟滞，精神分裂症，炎性疾病，再狭窄，免疫疾病，糖尿病，心血管疾病和哮喘。
-
8.发明申请4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) 审中-公开作为聚（ADP-核糖）聚合酶（PARP）抑制剂的4-氧代-4,5-二氢吡咯并[1,2-A]喹喔啉衍生物公开(公告)号：US20100152180A1
公开(公告)日：2010-06-17
申请号：US12376613
申请日：2007-08-06
申请人： Philip Jones , Uwe Koch , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
发明人： Philip Jones , Uwe Koch , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Carsten Schultz-Fademrecht
IPC分类号： A61K31/5377 , C07D487/04 , A61K31/4985 , A61P35/00 , A61P29/00 , A61P9/10 , A61P13/12 , A61P17/02 , A61P27/02 , A61P31/14 , A61P25/28 , A61P9/00 , A61P3/10
CPC分类号： C07D487/04
摘要： The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
摘要翻译： 本发明涉及式（I）化合物及其药学上可接受的盐或互变异构体，其是聚（ADP-核糖）聚合酶（PARP）的抑制剂，因此可用于治疗癌症，炎性疾病，再灌注损伤，缺血性疾病 ，中风，肾衰竭，心血管疾病，心血管疾病以外的血管疾病，糖尿病，神经变性疾病，逆转录病毒感染，视网膜损伤，皮肤衰老和紫外线诱发的皮肤损伤，以及用于癌症治疗的化学或放射增敏剂。
-
9.发明申请Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors 有权杂环取代酮衍生物作为组蛋白脱乙酰酶（HDAC）抑制剂公开(公告)号：US20100234374A1
公开(公告)日：2010-09-16
申请号：US12086812
申请日：2006-12-21
申请人： Philip Jones , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Raffaele Ingenito , Carsten Schultz-Fademrecht
发明人： Philip Jones , Jesus Maria Ontoria Ontoria , Rita Scarpelli , Raffaele Ingenito , Carsten Schultz-Fademrecht
IPC分类号： A61K31/4164 , C07D233/64 , A61K31/4172 , C07D401/06 , A61K31/4439 , C07D403/06 , A61K31/496 , C07D401/12 , A61K31/4709 , A61K31/454 , C07D417/12 , A61K31/427 , C07D413/12 , A61K31/5377 , C07D403/12 , A61K31/4196 , A61P35/00 , A61P25/28 , A61P25/00 , A61P25/18 , A61P29/00 , A61P37/02 , A61P9/10 , A61P9/00 , A61P11/06 , A61P3/10
CPC分类号： C07D233/64 , C07D401/12
摘要： The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
摘要翻译： 本发明涉及式（I）的化合物及其药学上可接受的盐和互变异构体。 本发明化合物是组蛋白脱乙酰酶（HDAC）的抑制剂，可用于治疗包括癌症在内的细胞增殖性疾病。 它们也可用于治疗神经变性疾病，精神发育迟滞，精神分裂症，炎性疾病，再狭窄，免疫疾病，糖尿病，心血管疾病和哮喘。
-
10.发明授权Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors 有权酰胺取代的吲唑作为聚（ADP-核糖）聚合酶（PARP）抑制剂公开(公告)号：US08071623B2
公开(公告)日：2011-12-06
申请号：US12006993
申请日：2008-01-08
IPC分类号： A61K31/445 , C07D231/56
CPC分类号： C07D401/10 , A61K31/4439
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，立体异构体或互变异构体，其是聚（ADP-核糖）聚合酶（PARP）的抑制剂，因此可用于治疗癌症，炎性疾病，再灌注损伤，缺血性疾病 ，中风，肾衰竭，心血管疾病，心血管疾病以外的血管疾病，糖尿病，神经变性疾病，逆转录病毒感染，视网膜损伤或皮肤衰老以及UV诱导的皮肤损伤，以及用作癌症治疗的化学和/或放射增敏剂。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.046 秒)
